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Comparative studies were performed in vitro to test the advocated superiority of infu-
sion over intermittent injection of aminoglycosides. Pseudomonas aeruginosa was
exposed to constant and to continuously decreasing (simulating in vivo kinetics) concen-
trations of gentamicin. In comparing the effect with similar area-under-the-concentration-
vs.-time curves, a substantial difference in killing and regrowth could not be demon-
strated. Regrowth occurred only when the gentamicin concentration had continuously
decreased below one fourth of the minimal inhibitory concentration for >2 hr. Expo-
sure of P. aeruginosa to gentamicin for 30 min was followed by persistent suppression
of bacterial regrowth for 1.4-1.9 hr. Thus, intermittent exposure of P. aeruginosa to
gentamicin is as effective as constant exposure in vitro. The demonstrated persistent
postantibiotic effect might cover in part the periods between intermittent doses of gen-
tamicin in vivo as well as in vitro.
Septicemia caused by Pseudomonas aeruginosa is
a major problem in leukopenic patients [1, 2]. The
infection is usually treated with the combination
of a fJ-Iactam antibiotic and an aminoglycoside.
Therapeutic failures with an aminoglycoside alone
are numerous and often occur despite the in vitro
demonstration of susceptibility by the causative
pathogen [3,4]. This discrepancy between in vitro
susceptibility and clinical outcome could in part be
explained by the fact that in routine sensitivity
testing the organisms are exposed to a constant
concentration of drug; in the clinical situation,
however, drug levels are changing and during the
interval between doses usually decrease below the
MIC for the infecting organism. The small thera-
peutic index of the aminoglycosides often does not
allow a substantial increase in dosing. In various
clinical studies, an attempt was therefore made to
improve the efficacy of aminoglycosides by ad-
ministering these drugs as constant infusions
rather than as intermittent injections [5-7]. How-
ever, no study so far has demonstrated a signifi-
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cant superiority of infusion over intermittent in-
jection of aminoglycosides. Pertinent in vitro
studies are lacking, although they would seem to
be an important first approach to analyzing the ef-
fect of changing concentrations of drug on the iso-
lated target.
In the present investigation, an in vitro model
was used to compare the efficacy of constant vs.
continuously decreasing concentrations of genta-
micin against P. aeruginosa. Patterns of killing
and regrowth of the test organisms were studied
when the in vivo t Y2 of gentamicin was simulated
in the model. Besides conventional inocula and
log-phase cultures, large inocula and lag-phase
organisms were also studied because infecting
organisms can often reach far higher numbers in
vivo than are usually studied in the test tube; it is
probable that some lag-phase organisms are pres-
ent even at the site of a virulent infection.
Materials and Methods
Organisms. P. aeruginosa strain no. ATCC
9721 (American Type Culture Collection, Rock-
ville, Md.) and clinical isolate no. 14974 (Institute
of Medical Microbiology, Bern, Switzerland) were
studied. All experiments were performed with
both strains.
Drug. Gentamicin sulfate was obtained from
Essex A.G., Lucerne, Switzerland.
Media. Mueller-Hinton broth (Ca", 2.4 mg/
liter; Mg'", 1.95 mg/liter) was used. For a few
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experiments, the broth was supplemented with
Ca" and Mg" according to the procedure of Strat-
ton and Reller [8]. Trypticase soy agar (Ca", 38.7
mg/liter; Mg", 17.0 mg/liter) was used for the cfu
determinations and for semiquantitative popula-
tion analyses on plates containing gentamicin in a
concentration gradient (0-8 ug/ml). Agar plates
with a higher concentration of divalent cations
were used to reduce the carry-over effect of genta-
micin activity for cfu determinations.
Inocula. Cultures that had been incubated for
24 hr were appropriately diluted whenever lag-
phase organisms were studied. Logarithmic-phase
organisms were obtained by diluting an overnight
culture 1:100 in prewarmed broth and by further
incubation at 37 C for 2 hr. This procedure
resulted in rv 107 viable organisms/ml.
Bacterial counts. Sterile 0.85070 NaCI was used
for serial dilutions of cultures as required. One-
tenth milliliter of each dilution was plated on
predried trypticase soy agar plates and, in some
experiments, on plates with a gentamicin concen-
tration gradient. The plates were inspected for
growth after incubation for 24 hr at 37 C.
Gentamicin assay. The agar diffusion method
using Bacillus subtilis strain no. ATCC 6051
(American Type Culture Collection) as the indica-
tor organism was used. Standard curves were con-
structed with samples of known gentamicin con-
centration in medium identical to that of the
unknown samples.
Determination of MIC, MBC, and minimal ac-
tive concentration (MAC) of gentamicin. The
MIC was determined repeatedly in broth [9]. The
MBC was defined as a reduction of ~3 log in the
number of viable organisms at 18-24 hr of incuba-
tion. The MAC, defined as the minimal drug con-
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centration resulting in a deviation from the growth
curve, was determined for various inocula by con-
structing killing curves using 4-ml broth cultures.
Model for in vitro simulation of in vivo tV2 of
gentamicin. The model for in vitro simulation of
the in vivo tY2 of gentamicin (figure 1) was similar
to the ones used by Grasso et al. [10] and Bergan
et al. [11]. All cultures and the flasks with diluent
were kept in a water bath at 37 C with shaking
beginning 30 min before the experiment was
begun. The experiment was started by addition of
the drug into the test culture and by starting the
peristaltic pump (Minipuls'" II Gilson; Synmedic
A.G., Zurich, Switzerland). The overflow was
regulated by the pressure in the tightly stoppered
test flask, thus keeping the volume of the test cul-
ture constant and yielding a continuous sample for
the determination of cfu. The t Y2 of the drug (2
hr) was calculated by the volume of the test cul-
tures (47-50 ml) and the inflow rate of the drug-
free diluent according to the equation: t Y2 = (In
2 x volume of test culture)/inflow rate. The tY2
was verified in each experiment by measuring the
volumes of the test culture and the outflow. This
procedure to calculate the drug kinetics in the sys-
tem was verified using phenol red as the indicator.
The A at 546 nm was measured in 0.1 N NaOH.
An almost perfect correlation was found between
the determined and the calculated levels of drug.
All experiments were performed in two to four
sets as shown in figure 1, using the same multi-
channel peristaltic pump. Thus, the cultures ex-
posed to decreasing concentrations of gentamicin
and those exposed to constant concentrations were
always tested in parallel. They were diluted iden-
tically with the exception that the diluent of the
constant-concentration cultures contained drug to
Figure 1. In vitro model used to
simulate the in vitro kinetics of genta-
micin against bacteria. Two to four
cultures were tested in parallel.
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keep the level in the test flask in a dynamic steady
state. An inevitable drawback to this model is the
dilution of the bacterial test culture, which in a
6-hr experiment was roughly eightfold.
Determination of persistent postantibiotic ef-
fect (PAE). The persistent PAE was determined
under static conditions. After the organisms were
exposed to gentamicin (at 37 C in a water bath
without shaking), the drug was removed by adding
10 mg of sterile cellulose phosphate powder
(Whatman, Maidstone, England) [12] suspended
in 0.1 ml of Mueller-Hinton broth, which after
vigorous shaking for 1 min in turn was removed
by centrifugation at 100 g for 5 min. The
organisms stayed in the supernatant. All cultures
were checked for residual drug (using a highly gen-
tamicin-susceptible clinical isolate of Aerobacter)
and then diluted at least 10-fold into fresh
prewarmed medium. The resulting subcultures (in
triplicate) were incubated again at 37 C in a water
bath without shaking and sampled hourly for
determination of cfu. Control cultures were treated
by the same procedure as the test cultures except
that the cellulose phosphate powder was added si-
multaneously with the drug. In preliminary experi-
ments the two P. aeruginosa strains grew in
Mueller-Hinton broth from which gentamicin had
been removed with cellulose phosphate powder as
well as in normal Mueller-Hinton broth; no dif-
ference was observed when the growth rate of
P. aeruginosa in normal Mueller-Hinton broth was
compared with that in a mixture of 90070 normal
Mueller-Hinton broth and 10070 Mueller-Hinton
broth from which added gentamicin had been re-
moved by the procedure described above. The
PAE was quantitated as previously reported [13].
(1) The mean time (hr) required for the cfu count
in the test subcultures (preexposed to gentamicin)
to increase by 1 log above the count of cfu deter-
mined at the start of the test subcultures was mea-
sured. (2) The mean time (hr) required for the cfu
count in the control subcultures to increase by 1
log above the count of cfu determined at the start
of the control subcultures was measured. (3) The
difference between the two values represents the
time during which the drug affects bacterial
growth after exposure (PAE time). In addition,
the PAE time was calculated after an increase in
cfu counts by 2 log in both test and control subcul-
tures. A prerequisite to evaluating the PAE experi-
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ments was that the PAE time calculated after 2 log
of regrowth in the subcultures was within
90070-110070 of the PAE time calculated after 1 log
of regrowth.
Calculations and statistical analysis of results.
The area under the curve (AVC) of gentamicin
concentration vs. time up to each sampling point
was calculated by the trapezoidal rule. All cfu de-
terminations in the kinetic model from test and
control cultures were corrected for the dilution of
the test organisms by the medium flow according
to the equation: log cfu corrected = log cfu deter-
mined + (log 2 x [t/tY2]), where tY2 is the value
calculated above and t is the time after starting the
continuous dilution. This correction is based on
the assumption that the outflushed bacteria would
behave exactly as the bacteria remaining in the test
flasks if by any means the outflushed bacteria
could have been retained.
In a recent study by Murakawa et al. [14], cfu
values in the kinetic model that they used were
similarly corrected for outflushed bacteria.
The comparison of regression lines was per-
formed by analysis of covariance [15].
Results
Effect of constant gentamicin concentrations.
The MIC of gentamicin for both strains of P. aerug-
inosa was 0.4 I-tg/ml. The MAC for both strains
was 0.1 J-lg/ml. MACs were identical for a small
(103 cfu/ml) and a conventional (105 .6 cfu/ml)
inoculum; in contrast, MICs and MBCs were inoc-
ulum-dependent. When cultures of >107 cfu/ml
were exposed to gentamicin in concentrations of
up to 2 IAg/ml (8 IAg/ml in Ca"> and Mgv-supple-
mented broth), regrowth after the initial killing
was common. Drug inactivation was excluded by
comparative determinations of gentamicin activity
in filtered (pore size, 0.45 lAm) samples of cultures
at the beginning and at the end of the experiment.
It could easily be shown on plates with a gentami-
cin concentration gradient that a more resistant
subpopulation was selected whenever such a large
inoculum was used.
Supplementation of Mueller-Hinton broth with
Ca" and Mg" increased the MICs, MACs, and
MBCs of gentamicin for both strains of P. aerugi-
nosa up to five to 10 times and shifted killing
curves accordingly. Supplementation did not
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otherwise alter the shape of the killing curves, nor
did it suppress the selection of more gentamicin-
resistant organisms.
Experiments performed under static conditions
demonstrated that killing by gentamicin was similar
for test organisms in the lag and logarithmic phases
of growth. Killing started within the first 30 min
of exposure to the drug and, up to 6 hr, was log-
linear thereafter. At 0.2-2 IJg of gentamicin/ml,
the bactericidal effect and the killing velocity cor-
related with the drug concentration. These find-
ings were of particular importance for evaluation
of the results obtained in the kinetic model.
Effect of continuously decreasing gentamicin
concentrations. Some killing curves obtained in
the kinetic model are shown in figure 2. The genta-
micin concentration in the two decreasing-concen-
tration cultures was initially 0.4 and 0.8 ug/ml,
respectively, and subsequently decreased with a
t Y2 of 2 hr. The two constant-concentration cul-
tures were exposed to 0.4 and 0.8 ug/ml, respec-
tively, in a dynamic steady state. Dilution of all
four cultures was started at 30 min after addition
of the drug. In the two decreasing-concentration
cultures, the drug concentration decreased to less
than the MAC by 4.25 and 6.25 hr, respectively,
after the drug was added.
Three features that were apparently not interre-
lated were consistently observed: (1) drug concen-
tration- and time-dependent killing of P. aerugi-
nosa up to 6 hr after addition of the drug (killing
phase); (2) persistent suppression of bacterial re-
growth at drug levels less than the MAC (postanti-
biotic phase); and (3) breakthrough growth in all
cultures after 6-8 hr (regrowth phase).
Killing phase. At constant and at decreasing
drug levels, the bactericidal effect of gentamicin
up to 6 hr proved to be both concentration- and
time-dependent. The individual points of killing
curves from 1 to 6 hr were, therefore, mathemati-
cally transformed and plotted as the log of the
percentage of surviving organisms vs. the log of
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Figure 2. Top, killing curves of
gentamicin against Pseudomonas
aeruginosa strain no. ATCC 9721 as
obtained in the kinetic model (figure
1) with unsupplemented Mueller-
Hinton broth; bottom, calculated
kinetics of gentamicin in continuous-
ly decreasing-concentration and
constant-concentration cultures. The
arrows indicate the time by which the
gentamicin concentration decreased
to less than the minimal active con-
centration (0.1 JJg/ml). At 8 hr a sec-
ond bolus was injected into the two
decreasing-concentration cultures to
increase the gentamicin concentra-
tion to the O-hrlevel; at 12hr the con-
centration was increased to twice the
O-hrvalue in all four cultures, and di-
lution was stopped. All cfu values are
corrected for the dilution effect on
the bacteria.
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Figure 3. Effect of gentamicin on large inocula of
Pseudomonas aeruginosa strain no. ATee 9721 in the
kinetic model (figure 1) with unsupplemented Mueller-
Hinton broth. The results from figure 2 are indicated by
triangles. Regression lines are calculated from data ob-
tained with an area under the curve of gentamicin con-
centration vs. time equal to and greater than the mini-
mal effective value (0.75 JJg/ml).
the corresponding AVC of drug concentration vs.
time. Figure 3 shows the results of the killing curves
displayed in figure 2 after mathematical transfor-
mation. The additional data points in figure 3
were derived from killing curves (data not shown)
obtained in the kinetic model at constant (1 and 2
JJg/ml) and decreasing (from initially 1 and 2
IJg/ml) concentrations of gentamicin. In sum-
mary, a good negative correlation for both modes
of dosing was found (for pooled data, r = 0.954)
between the log of the number of surviving
organisms and the log of the AVC. A difference
between the two methods of dosing, however,
could not be demonstrated with P. aeruginosa
strain no. ATCC 9721 (table 1). In additional ex-
periments, inocula of 106 cfu of P. aeruginosa/ml
were similarly exposed to decreasing and constant
concentrations of gentamicin. These results are
also shown in table 1. In some experiments, dilu-
tion of the test cultures to be compared was
started at 0, 0.5, or 1 hr after addition of the drug
to test further the hypothesis that the shape of the
drug concentration curve (in the range as seen in
vivo) might affect the bactericidal activity of gen-
tamicin. In none of these experiments or in those
performed with clinical isolate no. 14974 was a
significant difference between constant and decreas-
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ing concentrations of gentamicin demonstrated
when the effect of similar AVCs was compared. In
contrast, a comparison of the regression lines ob-
tained from experiments using large and small in-
ocula of P. aeruginosa strain no. ATCC 9721 dis-
closed a significant difference regarding the bac-
tericidal threshold AVC (minimally active AVC)
and slope (table 1). The results of experiments
with P. aeruginosa no. 14974 were similarly af-
fected by the size of the inoculum.
PAE. In most experiments simulating inter-
mittent dosing, the drug concentration decreased
to less than the MAC during the course of the exper-
iment; however, an immediate regrowth was not
observed (figure 2). In contrast, the organisms
stayed in a lag phase of growth which lasted 1-2
hr. Additional experiments under static conditions
were performed to explain this persistent drug ef-
fect. P. aeruginosa organisms were exposed to
gentamicin for a limited interval, after which the
drug was removed. Analyses of the regrowth pat-
tern revealed a persistent PAE which lasted for 1.4
hr when lag-phase organisms and 1.6 hr when log-
phase organisms had been exposed to a gentamicin
concentration of five times the MIC for 30 min
(figure 4). When an inoculum of 107 cfu/ml was
Table 1. Effect of mode of exposure to drug and in-
oculum size on the activity of gentamicin against Pseu-
domonas aeruginosa strain no. ATee 9721.
Minimal
Slope active AVC*
Mode of 107 . 5 106 107 . 5 106
exposure cfu/ml cfu/ml cfu/ml cfu/ml
Decreasing -4.84t -3.44t 0.77 0.21
Constant - S.24t -3.9t 0.76 0.21
Pooled -S.lS§ - 3.84§ 0.77 0.21
NOTE. The bacteria were exposed in vitro to constant or
to continuously decreasing (simulating in vivo kinetics) concen-
trations of gentamicin in the model shown in figure 1. Results
from 16 killing curves were plotted as the log of the percentage
of surviving organisms vs. the log of the area-under-the-drug-
concentration-vs.-time curve (AVC). Resulting regression lines
were compared for the significance of differences after analysis
of covariance [15] in the F-test. At each inoculum size the
difference between the two modes of exposure was not
significant.
* Bactericidal threshold AVC of gentamicin concentration
vs. time (in IJg x hr/ml). The values were calculated by
regression analysis.
t P< 0.05.
t P< 0.05.
§ P< 0.01.
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Discussion
posing particular therapeutic problems. Hence, we
focused on gentamicin and P. aeruginosa.
We were unable to demonstrate in vitro a supe-
riority of constant infusion over simulated inter-
mittent injection of similar doses of gentamicin.
Rather, keeping the inoculum the same, the effect
of gentamicin correlated with the log of the AVC
and was not dependent on the mode of how this
AVC was obtained. In the model used, the in vivo
kinetics of gentamicin were simulated by dilution
of the drug, and, as a consequence, the test orga-
nisms were diluted as well. A comparison between
the two simulated modes of dosing was neverthe-
less possible. Cultures exposed to decreasing drug
concentrations and those exposed to constant drug
concentrations in a dynamic steady state were
tested in parallel and identically diluted, all cfu
determinations were corrected for the inevitable
dilution of the bacteria, the comparison was made
between MICs and subinhibitory concentrations,
and large inocula were also studied. Finally, the
comparison was based on identical AVCs. Similar
studies, all focusing mainly on fJ-Iactam antibiot-
ics [10, 11, 14, 16, 17], have ignored at least in part
these factors, although they are relevant for the
evaluation of the antimicrobial efficacy of fluctu-
ating concentrations of drug.
The demonstrated persistent PAE of gentamicin
on P. aeruginosa was unexpected. It has not been
observed with Staphylococcus aureus [18]. How-
ever, we were able to demonstrate a PAE of genta-
micin on strains of P. aeruginosa (including no.
ATCC 27853) but not on Escherichia coli [13].
The regrowth of a gentamicin-selected sub-
population (frequently small-colony variants) of
P. aeruginosa was a major problem for the inter-
pretation of kinetic experiments looking at repeated
dosing. The regrowing population proved to be at
least partially gentamicin-resistant. Therefore, ex-
periments in which multiple doses were given, sim-
ulating clinical treatment with gentamicin, could
not be performed. Because these resistant variants
do not inactivate the drug and because ribosomal
resistance to gentamicin has, to our knowledge,
not been described, we assume that they are defec-
tive in aminoglycoside uptake. Such mutants have
been investigated by Bryan and Van Den Elzen
[19] and Bryan et al. [20].
We examined the effect of different modes of
gentamicin dosing on isolated target organisms in
vitro. In vivo, additional factors are involved and
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exposed for 2 hr to 0.4 IJg of gentamicin/ml (cor-
responding to the MIC for a conventional inocu-
lum), a PAE time of 1.3 hr was still demonstrated.
Regrowth phase. After 6-8 hr of exposure to
gentamicin, the test organisms usually started to
regrow. Regrowth occurred whether the culture
was exposed to constant or decreasing drug con-
centrations. The regrowing subpopulations were
at least partially resistant to a second simulated
bolus injection of gentamicin at 8 hr (figure 2).
Even a concentration of gentamicin twice that of
the initial concentration added at 12 hr (at which
time dilution was always stopped) had little or no
effect. The selected gentamicin-resistant subpopu-
lations harbored frequently, but not always,
small-colony-forming variants. Pure populations
of small-colony variants were selected in some ex-
periments, but when subcultured these variants
were unstable in morphology and gentamicin re-
sistance.
Figure 4. Persistent postantibiotic effect (PAE) of
short exposure (30 min) of lag-phase Pseudomonas
aeruginosa strain no. ATCC 9721 organisms to five
times the MIC of gentamicin. Data are means ± SD of
triplicate determinations. Arrows indicate the time re-
quired for l-log regrowth to occur in the treated and the
control cultures.
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might be of paramount importance. Though this
proposal is controversial, the mode of aminogly-
coside administration might affect the penetration
of the drug into tissues and bronchial secretions
[21-23]. Further, the oxygen-dependent mecha-
nism of aminoglycoside uptake in susceptible bac-
teria might well be of minor importance in in-
fected tissues because oxygen can be scarce at
these sites [24]; the lag phase of the bactericidal ef-
fect of gentamicin could be considerably longer,
and the PAE might be absent in vivo. Thus, addi-
tional studies in vivo, both in animal models and
in patients, are needed to establish the role of dos-
ing regimens on the efficacy of aminoglycoside
antibiotics.
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